ArticleJournal of endocrinological investigation2011
Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in Type 2 diabetes.
Article in Journal of endocrinological investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice.Physiological reports · 2026Article
- Reactive carbonyl species in health and chronic disease: from methylglyoxal to an integrative network of metabolic regulation.Cardiovascular diabetology · 2026Review
- Mechanistic Link Between Glyoxalase 1 Expression and Methylglyoxal-Induced Oncogenic Stress in Prostate Cancer.bioRxiv : the preprint server for biology · 2025Article
- The Human Glyoxalase Gene Family in Health and Disease.Chemical research in toxicology · 2022Review
- Clinical Implications of Glyoxalase1 Gene Polymorphism and Elevated Levels of the Reactive Metabolite Methylglyoxal in the Susceptibility of Type 2 Diabetes Mellitus in the Patients from Asir and Tabuk Regions of Saudi Arabia.Journal of personalized medicine · 2022Article
- The Glyoxalase System in Age-Related Diseases: Nutritional Intervention as Anti-Ageing Strategy.Cells · 2021Review
- Polymorphisms in Glyoxalase I Gene Are Not Associated with Glyoxalase I Expression in Whole Blood or Markers of Methylglyoxal Stress: The CODAM Study.Antioxidants (Basel, Switzerland) · 2021Article
- Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2020Review
- Glycation in Huntington's Disease: A Possible Modifier and Target for Intervention.Journal of Huntington's disease · 2019Review
- GLO1 gene polymorphisms and their association with retinitis pigmentosa: a case-control study in a Sicilian population.Molecular biology reports · 2018Article
- The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality.Cell metabolism · 2018Review
- Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children.Hormone research in paediatrics · 2016Review
- Advanced glycation End-products (AGEs): an emerging concern for processed food industries.Journal of food science and technology · 2015Review
- Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.Translational research : the journal of laboratory and clinical medicine · 2012Review
- Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.The review of diabetic studies : RDS · 2012Review
- Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes.International journal of vascular medicine · 2012Article
- Expression analysis ofPakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlyoxalase I (GLO1), which is the major enzyme that catalyzes the metabolism of methylglyoxal (MG), may play an important role in the pathogenesis of diabetic microvascular complications.
aimTo investigate whether the C-7T and A419C polymorphisms of the GLO1 gene are associated with nephropathy and retinopathy in Chinese Type 2 diabetic patients. SUBJECTS AND
methodsA total of 364 Type 2 diabetic patients and 301 healthy controls were enroled in the study. Diabetic microvascular complications were determined by urinary albumin excretion measurements and ophthalmological examinations. Genetic analyses were performed using either Taqman PCR or direct sequencing. The effect of C-7T polymorphism on promoter activity was measured by reporter gene assays.
resultsThe albumin/ creatinine ratio (ACR) and prevalence of nephropathy and retinopathy were significantly higher in diabetic patients with GLO1 -7CC genotype than in patients with -7CT and -7TT genotypes (p=0.02, p=0.02, and p=0.04, respectively). The - 7CC genotype is independently associated with ACR (β=0.13, p=0.01) and the risk for retinopathy [odds ratio (OR): 2.30, 95% confidence interval (CI): 1.25-4.24, p<0.01]. The luciferase activity of the -7T promoter was higher than that of the -7C promoter (13.2±0.2 vs 11.7±0.8, p=0.04). No differences were found between ACR and the prevalence of nephropathy and retinopathy for A419C polymorphism in Type 2 diabetic patients.
conclusionsGLO1 C-7T polymorphism alters promoter activity and confers susceptibility to nephropathy and retinopathy to Type 2 diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.